Global /United Kingdom /Healthcare /Drug Manufacturers - General /AZN
chevron_leftBack

AstraZeneca PLC

AZN
LSE: AZN Delayed
10,384GBX 0.2%
138.11 USD
As of 24 April 2025, AstraZeneca PLC has a market cap of $213.71B USD, ranking #55 globally and #1 in the United Kingdom. It ranks #8 in the Healthcare sector, and #6 in the Drug Manufacturers - General industry.
Global Rank
55
Country Rank
1
Sector Rank
8
Industry Rank
6
Key Stats
Market Cap
$213.71BUSD
160.68B GBP
Enterprise Value
$240.29BUSD
180.66B GBP
Revenue (TTM)
$57.45BUSD
43.19B GBP
EBITDA (TTM)
$18.66BUSD
14.03B GBP
Net Income (TTM)
$7.47BUSD
5.62B GBP
EBITDA Margin
32%
Profit Margin
13%
PE Ratio
28.8
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Pascal Claude Soriot open_in_new
Employees
94,300
Founded
1992
Website
astrazeneca.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
0.2% 2.5% -11% -6% -12% -7.9%
Upcoming Earnings
Earnings Date
Tue, Apr 29

Markets

Exchange Ticker Price
London Stock Exchange
MIC: XLON
PRIMARY
AZN
ISIN: GB0009895292
Shares Out.:
1.551B1 Shares Float: 1.47B2
TV:
SA:
YF:
GF:
BA:
AZN
MS:
10.38K GBX
London Stock Exchange
MIC: XLON
0A4J
AstraZeneca PLC ADR
ISIN: US0463531089
Shares Out.:
3.101B1 Shares Float: 3.101B2
TV:
SA:
YF:
GF:
BA:
MS:
67.00 USD
Nasdaq Stockholm
MIC: XSTO
AZN
ISIN: GB0009895292
TV:
SA:
YF:
GF:
BA:
AZN
MS:
1.33K SEK
NASDAQ
MIC: XNAS
AZN
AstraZeneca PLC ADR
ISIN: US0463531089
Shares Out.:
3.101B1 Shares Float: 3.101B2
TV:
SA:
YF:
AZN
GF:
NQ:
AZN
BA:
AZN
MS:
68.51 USD
Mexican Bolsa
MIC: XMEX
AZN1 (AZN1/N)
AstraZeneca PLC
ISIN: GB0009895292
TV:
SA:
YF:
GF:
BA:
MS:
2.87K MXN
OTC Markets
MIC: OTCM
AZNCF
ISIN: GB0009895292
TV:
SA:
YF:
GF:
BA:
MS:
129.15 USD
Deutsche Börse Xetra
MIC: XETR
ZEG
ISIN: GB0009895292
TV:
SA:
YF:
GF:
BA:
ZEG
MS:
121.75 EUR
Frankfurt Stock Exchange
MIC: XFRA
ZEG
ISIN: GB0009895292
TV:
SA:
YF:
GF:
BA:
ZEG
MS:
118.75 EUR
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Similar Companies

Industry: Drug Manufacturers - General (United Kingdom)
Name
Market Cap diff.
GSK plc
GSK
$74.32B
55.88B GBP
-65%
Industry: Drug Manufacturers - General (Global)
Name
Market Cap diff.
Eli Lilly and Co.
LLY
$744.81B
249%
Johnson & Johnson
JNJ
$374.44B
75%
AbbVie Inc.
ABBV
$313.2B
47%
Novo Nordisk A/S
NOVO-B
$276.68B
1.82T DKK
29%
Roche Holding AG
RO
$250.88B
207.2B CHF
17%